A5006026980- Multiple Myeloma Research and Treatments
- Pulmonary Hypertension Research and Treatments
- Cardiovascular Conditions and Treatments
- Cardiovascular Effects of Exercise
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Safe Handling of Antineoplastic Drugs
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Congenital Heart Disease Studies
- Congenital heart defects research
- Blood Pressure and Hypertension Studies
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Cardiomyopathy and Myosin Studies
Nference (United States)
2023-2024
Health First
2024
Mayo Clinic
2023
Background Left atrial ( LA ) enlargement, congestive heart failure CHF ), and aortic thromboembolism ATE are associated with decreased survival in cats hypertrophic cardiomyopathy HCM but the prognostic value of echocardiographic variables has not been well characterized. Hypothesis/Objectives We hypothesized that assessment left ventricular LV diastolic systolic function would have . Animals Two hundred eighty‐two diagnosed Methods Clinical records affected seen at Royal Veterinary College...
Early diagnosis of pulmonary hypertension (PH) is critical for effective treatment and management. We aimed to develop externally validate an artificial intelligence algorithm that could serve as a PH screening tool, based on analysis standard 12-lead ECG.
PURPOSE: Median duration of daratumumab (DARA) administration for treatment multiple myeloma is 3-7 hours the intravenous formulation (DARA IV) and 3-5 minutes subcutaneous SC). Here, we describe clinical characteristics DARA using a novel method data extraction from electronic health records. METHODS: Time-based measurements were extracted scheduling/pharmacy software program that tracked patient movement through appointments patients initiating in Mayo Clinic infusion centers April 5,...
PURPOSE Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their use is associated with immune-related adverse events (irAEs). Estimating the prevalence and patient impact of these irAEs in real-world data setting critical for characterizing benefit/risk profile ICI therapies beyond clinical trial population. Diagnosis codes, such as International Classification Diseases do not comprehensively illustrate a patient's care journey offer no insight into drug-irAE...
PURPOSE Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity (ICANS). Early teclistamab users commonly received SUD in hospital setting. This study aimed evaluate safety health care resource utilization (HRU) real-world patients multiple myeloma who an outpatient METHODS was retrospective using Mayo Clinic's electronic medical records from October 26, 2022, 31, 2023. Patient...
A 7-month-old intact female Cocker Spaniel weighing 7.7 kg was presented for investigation of a heart base murmur. The dog free from clinical signs. There grade IV/VI pansystolic murmur localized over the left base. Femoral pulses were normal volume and character. Routine serum biochemistry hematology unremarkable. Echocardiography showed increased ventricular internal end diastolic diameter (LVIDD) at 4.2 cm (reference range, 2.3–3.4 cm1) systolic (LVIDS) 2.8 1.4–2.4 cm1), mildly atrial...